New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
17. Januar 2023 16:30 ET
|
Aridis Pharmaceuticals, Inc.
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 ...